6446 Panoramica delle azioni PharmaEssentia Corporation, un'azienda biofarmaceutica che si occupa del trattamento delle malattie umane a Taiwan e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
PharmaEssentia Corporation Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per PharmaEssentia Prezzi storici delle azioni Prezzo attuale dell'azione NT$699.00 Massimo di 52 settimane NT$735.00 Minimo di 52 settimane NT$281.00 Beta 0.56 Variazione di 1 mese -3.98% Variazione a 3 mesi 12.02% Variazione di 1 anno 125.85% Variazione a 3 anni 162.78% Variazione a 5 anni 547.22% Variazione dall'IPO 233.19%
Notizie e aggiornamenti recenti Vedi altri aggiornamenti
PharmaEssentia Corp Announces China NMPA has Accepted the Phase III Clinical Trial Application of P1101 for Pre-fibrotic/Early PMF or Overt PMF at Low or Intermediate-1 Risk Jan 15
PharmaEssentia Corporation (TWSE:6446) Stock Rockets 25% But Many Are Still Ignoring The Company Jan 08
PharmaEssentia Corporation Announces Positive Topline Phase 3 Data from Surpass-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia Jan 07
PharmaEssentia Corporation Announces Positive Topline Results from Phase 3 Clinical Trial of P1101 for ET Jan 05
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors to TFDA Jan 03
Does PharmaEssentia (TWSE:6446) Have A Healthy Balance Sheet? Dec 18
Pharmaessentia Corporation Appoints Joseph R. Horvat as Global Chief Commercial Officer Dec 05
PharmaEssentia Corporation Announces Nine Data Presentations at ASH Annual Meeting Nov 26
Consensus EPS estimates fall by 18% Nov 21
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 16
PharmaEssentia Corporation to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
PharmaEssentia Corporation Announces Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia (ET) Oct 18
PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle Sep 07
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings Aug 20
Consensus EPS estimates increase by 55% Aug 20
Second quarter 2024 earnings: EPS exceeds analyst expectations Aug 14
PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
Consensus EPS estimates increase by 21% Jul 18
Price target increased by 39% to NT$581 Jul 17
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors Jul 03
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues Jul 02
Now 24% overvalued after recent price rise Jun 26
New minor risk - Share price stability Jun 14 Pharmaessentia Corporation Announces Appointments to Board of Directors
PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA May 23
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 15 PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024 May 08
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA Apr 27
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia Apr 26 PharmaEssentia Corporation announced a financing transaction Apr 03
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation? Apr 02
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA Mar 06
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration Mar 05
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 28
PharmaEssentia Corporation, Annual General Meeting, May 27, 2024 Feb 27
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA Jan 18
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 14
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia Oct 27
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China Sep 21
New minor risk - Share price stability Aug 15
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 11
PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts Aug 09
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV) Jul 01
Forecast breakeven date moved forward to 2023 May 23
PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong May 08
Price target increased by 32% to NT$585 Apr 17
Full year 2022 earnings: EPS exceeds analyst expectations Mar 02
PharmaEssentia Corporation Submits New Drug Registration of BESREMi for PV in Malaysia Jan 17 PharmaEssentia Corporation Announcement of Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia
Third quarter 2022 earnings: EPS misses analyst expectations Nov 18
Price target increased to NT$443 Nov 16
Less than half of directors are independent Nov 16
AOP Files Civil Action Against the PharmaEssentia Corporation in Middlesex Superior Court for the Commonwealth of Massachusetts Oct 19
PharmaEssentia Corporation Receives "Prior Authorization for Import of Medicines" for Besremi In Macau Sep 16
Taiwan Ministry of Health and Welfare Approves the Pharmaceutical Plant with GMP to Athenex for KX01 (Tirbanibulin) in the U.S Sep 14
PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan Sep 07
PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan Sep 06
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 16
PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer Aug 02
PharmaEssentia Corporation Announces Preliminary Results of the Phase II Clinical Trial of Ropeginterferon Alfa-2B(P1101) for the Treatment of PV in China Aug 01
PharmaEssentia Corporation Announces Submission of Application to TFDA for Change of Study Purpose from IIT to Company-Sponsored Clinical Trial for Treatment of Covid-19 by Ropeginterferon Alfa-2B Jul 09
PharmaEssentia Corporation Receives Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia(ET) Jun 06
PharmaEssentia Corporation's Subsidiary PharmaEssentia USA Corporation Appoints Meredith Manning to President of the Americas May 18
Price target increased to NT$357 Apr 27
Less than half of directors are independent Apr 27 PharmaEssentia Corporation announced a financing transaction Apr 14
Consensus revenue estimates fall by 29% Mar 09
PharmaEssentia Corporation, Annual General Meeting, May 27, 2022 Mar 04
Forecast to breakeven in 2023 Mar 04
Consensus forecasts updated Feb 17
German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages Feb 16
Third quarter 2021 earnings released: NT$2.70 loss per share (vs NT$2.42 loss in 3Q 2020) Nov 17
Forecast to breakeven in 2023 Nov 17
Second quarter 2021 earnings released: NT$2.08 loss per share (vs NT$0.92 loss in 2Q 2020) Aug 18
Consensus revenue estimates fall to NT$568.0m Jul 14
Price target decreased to NT$98.00 Jul 14
First quarter 2021 earnings released: NT$2.63 loss per share (vs NT$1.30 loss in 1Q 2020) May 15
AOP Orphan Reports Full Validity of Arbitral Award Against PharmaEssentia Mar 26
PharmaEssentia Corporation Announces Complete Response Letter for the Drug BESREMi® by US Food & Drug Administration Mar 17
PharmaEssentia Corporation Provides U.S. Regulatory Update on Ropeginterferon Alfa-2B-Njft for the Treatment of Polycythemia Vera Mar 15
Analysts lower revenue estimates to NT$1.62b Mar 12
Price target raised to NT$110 Mar 12
PharmaEssentia Corporation, Annual General Meeting, May 26, 2021 Mar 09 Rendimenti per gli azionisti 6446 TW Biotechs TW Mercato 7D 1.7% 4.2% -0.7% 1Y 125.8% 17.7% 26.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 6446 ha superato il TW Biotechs che ha restituito 17.7 % nell'ultimo anno.
Rendimento vs Mercato: 6446 ha superato il mercato TW che ha restituito 26.3 % nell'ultimo anno.
Volatilità dei prezzi Is 6446's price volatile compared to industry and market? 6446 volatility 6446 Average Weekly Movement 5.9% Biotechs Industry Average Movement 5.2% Market Average Movement 4.5% 10% most volatile stocks in TW Market 8.0% 10% least volatile stocks in TW Market 2.1%
Prezzo delle azioni stabile: 6446 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato TW.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 6446 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda PharmaEssentia Corporation, azienda biofarmaceutica, si occupa del trattamento di malattie umane a Taiwan e a livello internazionale. I suoi prodotti includono il Ropeginterferone alfa-2b, utilizzato per il trattamento della leucemia mieloide cronica, della leucemia a cellule T, della mielofibrosi precoce, della policitemia vera e della trombocitemia essenziale. L'azienda sviluppa anche TCRT, anti PD-1, PEG-citochina X,Y e nuovi checkpoint abs per il trattamento dei tumori solidi; P1101 + anti PD-1 per il trattamento del carcinoma epatocellulare e PEG-GCSF per il trattamento della neutropenia.
Mostra di più PharmaEssentia Corporation Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di PharmaEssentia con la sua capitalizzazione di mercato? 6446 statistiche fondamentali Capitalizzazione di mercato NT$232.69b Guadagni(TTM ) NT$1.85b Ricavi(TTM ) NT$8.32b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 6446 Conto economico (TTM ) Ricavi NT$8.32b Costo del fatturato NT$1.07b Profitto lordo NT$7.25b Altre spese NT$5.40b Guadagni NT$1.85b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 5.54 Margine lordo 87.10% Margine di profitto netto 22.19% Rapporto debito/patrimonio netto 0.3%
Come si è comportato 6446 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/07 18:10 Prezzo dell'azione a fine giornata 2025/02/07 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche PharmaEssentia Corporation è coperta da 9 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione null null Capital Securities Corporation Jianzheng Wu Capital Securities Corporation Wangbin Zhou Citigroup Inc
Mostra 6 altri analisti 
